Skip to content
value.today

Intersect ENT, Inc.

Total raised
$52 M
2 rounds on record
Latest round
$21 M
Feb 2013
First round on record
Oct 2010
Today
Private
See the company page

Intersect ENT, Inc. is listed today as Intersect Ent: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Intersect ENT, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2013$21 MNo. 2$10 to $50 million

Intersect ENT, Inc.: Raise no. 2, Feb 2013

Investors in this round

34 investors had bought by the notice of Mar 29, 2013: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Intersect ENT, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $31 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lisa D. Earnhardt · Executive Officer, Director
  • Monika A. De Martini · Executive Officer
  • Richard E. Kaufman · Executive Officer
  • Casey M. Tansey · Director
  • Casper H. de Clercq · Director
  • Dana G. Mead, Jr. · Director
  • Frederic H. Moll · Director
  • Mark A. Fletcher · Director
  • Rick M. Anderson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Monika A. De Martini, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 29, 2013. Read the notice at the SEC.

equitySEC
Oct 2010$31 MNo. 1$10 to $50 million

Intersect ENT, Inc.: Raise no. 1, Oct 2010

Investors in this round

17 investors had bought by the notice of Sep 1, 2011: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Intersect ENT, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lisa D. Earnhardt · Executive Officer, Director
  • Monika A. De Martini · Executive Officer
  • Richard E. Kaufman · Executive Officer
  • Casey M. Tansey · Director
  • Dana G. Mead, Jr. · Director
  • Evan S. Melrose · Director
  • Frederic H. Moll · Director
  • Mark A. Fletcher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Monika A. De Martini, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 1, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Intersect ENT, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2013).

    SEC Form D · Mar 2013

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2013

That is all the official record says: Intersect ENT, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Intersect ENT, Inc. are on record.

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Intersect ENT, Inc.
InvestorKindAmountRoundRoleSource
Amy WolbeckPersonnot statednot statedHeld Series D preferred stock (Form 3, 2014)SEC Form 3
Frederic H. MollPersonnot statednot statedHeld Series A, B, C and D preferred stock, director (Form 3, 2014)SEC Form 3
Kleiner Perkins Caufield & Byers XI-A LPFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Kleiner Perkins Caufield & Byers XI B LPFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
KPCB XI Associates, LLCOthernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Norwest Venture Partners XII, LPVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Norwest Venture Partners XI, LPVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Pinto Technology Ventures GP II, L.P.Venture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Pinto TV GP CO LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Presidio Management Group IX, L.L.C.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
PTV Sciences II L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Richard E. KaufmanPersonnot statednot statedHeld Series D preferred stock (Form 3, 2014)SEC Form 3
Robert H. Binney Jr.Personnot statednot statedHeld Series D preferred stock (Form 3, 2014)SEC Form 3
U S Venture Partners IX L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Intersect ENT, Inc.
NameRoleNamed in
Lisa D. EarnhardtExecutive officerMar 2013
Monika A. De MartiniExecutive officerMar 2013
Richard E. KaufmanExecutive officerMar 2013
Casey M. TanseyDirectorMar 2013
Casper H. de ClercqDirectorMar 2013
Dana G. Mead, Jr.DirectorMar 2013
Frederic H. MollDirectorMar 2013
Lisa D. EarnhardtDirectorMar 2013
Mark A. FletcherDirectorMar 2013
Rick M. AndersonDirectorMar 2013
Evan S. MelroseDirectorSep 2011

About

Health care equipment company, subsidiary of Medtronic.